Showing results (51-60 of 168) with videos related to

Sort By:
Pageof 17
Chemistry & Biology|November 29, 2011
Antagonism of chemical genetic interaction networks resensitize MRSA to β-lactam antibioticsSang Ho Lee, Lisa Wang Jarantow, Hao Wang, et al.
Head & Neck|February 28, 2008
Adenoid cystic carcinoma of the larynx: a 40-year experienceRoger V Moukarbel, David P Goldstein, Brian O'Sullivan, et al.
Human Molecular Genetics|February 21, 2009
Notch signaling contributes to the pathogenesis of human osteosarcomasFeyza Engin, Terry Bertin, Ou Ma, et al.
Nature Communications|December 31, 2024
Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancersRuishan Liu, Shemra Rizzo, Lisa Wang, et al.
Pediatric Blood & Cancer|May 12, 2026
Venous Thromboembolism in Pediatric Bone Sarcoma Patients: A 10-Year, Single-Institution Experience Encompassing the COVID-19 PandemicSarah Kappa, Shou Xu, Mark Zobeck, et al.
The Plant Cell|March 11, 2019
RUBY, a Putative Galactose Oxidase, Influences Pectin Properties and Promotes Cell-To-Cell Adhesion in the Seed Coat Epidermis of ArabidopsisKrešimir Šola, Erin J Gilchrist, David Ropartz, et al.
Biochemical and Biophysical Research Communications|June 12, 2010
Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesisMohammad H Pourgholami, Levon M Khachigian, Roger G Fahmy, et al.
Journal of Medical Economics|May 24, 2017
Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare systemFuraha Kariburyo, Yuexi Wang, I-Ning Elaine Cheng, et al.
BMC Infectious Diseases|November 13, 2016
Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimensThomas Iftner, Lisa Wang, Angelika Iftner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 18, 2010
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II ConsortiumStephen A Welch, Hal W Hirte, Laurie Elit, et al.
Pageof 17